Geron (NASDAQ:GERN) announced its earnings results on Sunday. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01), MarketWatch Earnings reports. Geron had a negative return on equity of 43.76% and a negative net margin of 21,631.02%.
GERN stock traded down $0.02 during mid-day trading on Wednesday, reaching $1.37. The company had a trading volume of 5,074 shares, compared to its average volume of 3,318,178. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.60 and a current ratio of 9.60. Geron has a fifty-two week low of $1.22 and a fifty-two week high of $2.40. The company has a market capitalization of $436.39 million, a price-to-earnings ratio of -3.97 and a beta of 1.50. The firm has a fifty day simple moving average of $1.49 and a 200 day simple moving average of $1.72.
Several brokerages have recently weighed in on GERN. B. Riley reaffirmed a “buy” rating on shares of Geron in a research note on Wednesday, February 17th. HC Wainwright reissued a “buy” rating on shares of Geron in a research note on Thursday, April 8th. Finally, Zacks Investment Research cut Geron from a “hold” rating to a “sell” rating in a report on Monday, February 22nd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $3.83.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Story: What is a Roth IRA?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.